Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/NiaStase®) in Subjects With Brain Contusions

NCT00123591 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00123591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00123591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/NiaStase®) in Subjects With Brain Contusions
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
May 31, 2006
Enrollment
96 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, trauma